Navigation Links
Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting And Stapling Device
Date:5/15/2013

REDWOOD CITY, Calif., May 15, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced it has completed enrollment in the European clinical study for its MicroCutter XCHANGE™ 30, a cartridge-based cutting/stapling device with a 5-millimeter shaft diameter and cross-sectional area more than six times smaller than standard 12-millimeter surgical staplers used today. The trial is designed to evaluate the safety of the XCHANGE 30 in a variety of gastrointestinal surgical procedures to support a 510(k) filing for market clearance from the U.S. Food and Drug Administration (FDA).

"Based on consistent product performance and positive unaudited clinical outcomes of the trial to date, following standard statistical analyses we expect to file regulatory documents with the FDA in the third quarter of calendar 2013," said Bernard A. Hausen , M.D., Ph.D., president and chief executive officer of Cardica. "We would like to express our sincere thanks to the investigators and patients for their enthusiasm in participating in the trial to advance the XCHANGE 30, the smallest cutting and stapling device available today."

The prospective, single-arm, multi-center, non-inferiority clinical study enrolled 160 patients at seven centers in Germany. The results of the procedures will be compared to historical adverse event reports for similar procedures performed with currently available stapling devices. Typical adverse events associated with current surgical staplers include staple line leakage, staple line bleeding, staple line strictures and surgical infections.

About Cardica 
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 45,200 units throughout the world. In addition, Cardica is developing the Cardica® MicroCutter XCHANGE™ 30, a cartridge-based microcutter device with a five-millimeter shaft diameter, and the Cardica® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device with an eight-millimeter shaft. Both MicroCutter devices are designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 30 and XCHANGE 45 products require 510(k) review and are not yet commercially available in the U.S.

Forward-Looking Statements
The statements in this press release regarding Cardica's expectation that it will file regulatory documents with the FDA (510(k) filing for market clearance) in the third quarter of calendar 2013,  is a "forward-looking statement." There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including:  that Cardica may not be successful in its efforts to further develop the XCHANGE 30 due to unanticipated technical or other difficulties; that the XCHANGE 30 may face unanticipated development, regulatory, or manufacturing delays; that Cardica's intellectual property rights may not provide adequate protection to enable further development of the XCHANGE 30; that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons; and that Cardica may not have sufficient funds to develop the XCHANGE 30, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Current Report on Form 10-Q for the quarter ended December 31, 2012, filed with the filed with the U.S. Securities and Exchange Commission (SEC) on February 8, 2013. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the SEC, available at www.sec.gov.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Fiscal 2013 Third Quarter Financial Results
2. Cardica to Announce Fiscal 2013 Third Quarter Financial Results On Tuesday, April 30, 2013
3. Cardica Prices Public Offering Of Common Stock
4. Cardica Announces Proposed Public Offering of Common Stock
5. Cardica Updates Enrollment Progress In European Clinical Trial
6. Cardica Announces Fiscal 2013 Second Quarter Financial Results
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
9. Cardica Announces Fiscal 2013 First Quarter Financial Results
10. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
11. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the ... an agreement with the University of Pittsburgh for ... standard animal models of ocular virus infections. ... Romanowski has extensive experience in ocular virus infections ... Eric Romanowski , Research Director. Dr. Romanowski has ...
(Date:2/11/2016)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) (the ... of a once-daily, oral therapy for the treatment of ... Dr. Maya Halpern , has notified the Company that ... and from its Board of Directors effective as of ... Allen Baharaff . Mr. Baharaff continued, "While ...
(Date:2/11/2016)... 11, 2016 Indiso ltd , a ... of pulmonary and respiratory diseases announced today positive results ... COPD and asthma patients show improvements in respiratory functions ... --> Upper and lower respiratory tract ... developed world and reached epidemic level. Increasing number of ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... their ongoing community involvement program, introduces a new charity campaign to raise funds ... are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) ...
(Date:2/11/2016)... ... 2016 , ... From March 4 through 6, Hidrex ... at the Walter E. Washington Convention Center in Washington, D.C. , At the ... hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will be talking ...
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... ... ... Early this week, Team Iconic at J. Walter Thompson and Nestlé KITKAT ... global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa Plan aims ... activities that focus on better farming, better lives and better cocoa. In order to ...
Breaking Medicine News(10 mins):